Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.68 USD
370.82 M USD
5.68 B USD
About UCB
Sector
CEO
Jean-Christophe Tellier
Headquarters
Brussels
Website
Founded
1925
FIGI
BBG000CL1G57
UCB SA engages in the research and development of biopharmaceuticals products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.
UCB.BR short term bullish potential to challenge ATHConclusion:
A substantial break above 100, preferably above 107 signals a short term bullish potential, challenging ATH and beyond.
A drop below 75 on the other hand renders long term bearish or at least choppy consolidation.
For short term play targeting 108 minimally, with tight stop just under 96
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.